Iceland· IS-EU/1/13/885/002
Kadcyla
A trastuzumab emtansine product containing trastuzumabum emtansinum inn, registered in Iceland by Roche Registration GmbH*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Trastuzumab emtansine is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD03 (trastuzumab emtansine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Trastuzumab emtansine · ATC L01FD03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab emtansine costs, country by country.
Normalised to the WHO defined daily dose (12 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trastuzumab emtansine · price per daily dose (12 mg)
USD · FX 28 Sept 2026
- CH Switzerland$237.25
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Trastuzumabum emtansinum INN
- Manufacturer
- Roche Registration GmbH*
- Country
- Iceland (IS)
- ATC code
- L01FD03
- ATC class
- Trastuzumab emtansine
- Defined daily dose
- 12 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean1211041 hgl x1 pakkiISK 470469
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
256 interactions on record for trastuzumab emtansine.
Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab emtansine · interactions on record
256 records
- 62 severe
- 194 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab emtansine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKadcylaRoche Registration GmbH
- SpainKADCYLA 160 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- United KingdomKadcyla 160mg powder for concentrate for solution for infusion vialsRoche Products Ltd
- NorwayKadcylaRoche Registration GmbH
- PolandKadcylaRoche Registration GmbH
- BelgiumKadcyla 160 mgRoche Registration
- SwedenKadcyla 160 mg Pulver till koncentrat till infusionsvätska, lösningRoche Registration GmbH
- CzechiaKADCYLARoche Registration GmbH, Grenzach-Wyhlen
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Kadcyla
- Norway · Kadcyla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cfc34c47-bee1-488d-b378-c0189edb947c GET /v1/drugs/cfc34c47-bee1-488d-b378-c0189edb947c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FD03",
"marketed": true,
"strength": "160 mg",
"ma_number": "EU/1/13/885/002",
"substance": "Trastuzumabum emtansinum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "41593"
}See everything about trastuzumab emtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.